Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Clinical trial NCT03529084 · WITHDRAWN
Trial details
- NCT number
- NCT03529084
- Sponsor
- Novartis Pharmaceuticals
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-24
- Primary completion
- 2020-08-13
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.